<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812449691</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812449691</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Special Issue Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Therapeutic Developments in Friedreich Ataxia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wilson</surname>
<given-names>Robert B.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0883073812449691">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073812449691"/>
</contrib>
<aff id="aff1-0883073812449691"><label>1</label>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="editor">
<name>
<surname>Maria</surname>
<given-names>Bernard L.</given-names>
</name>
<degrees>MD, MBA</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0883073812449691">Robert B. Wilson, MD, PhD, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Room 509A, Stellar-Chance Laboratories, 422 Curie Boulevard, Philadelphia, PA 19104, USA Email: <email>WilsonR@mail.med.upenn.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>9</issue>
<issue-title>Special Issue: Childhood Ataxia</issue-title>
<fpage>1212</fpage>
<lpage>1216</lpage>
<history>
<date date-type="received">
<day>9</day>
<month>1</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>4</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Friedreich ataxia is an inherited, severe, progressive neuro- and cardiodegenerative disorder for which there currently is no approved therapy. Friedreich ataxia is caused by the decreased expression and/or function of frataxin, a mitochondrial matrix protein that binds iron and is involved in the formation of iron-sulfur clusters. Decreased frataxin function leads to decreased iron-sulfur cluster formation, mitochondrial iron accumulation, cytosolic iron depletion, oxidative stress, and mitochondrial dysfunction. Cloning of the disease gene for Friedreich ataxia and elucidation of many aspects of the biochemical defects underlying the disorder have led to several major therapeutic initiatives aimed at increasing frataxin expression, reversing mitochondrial iron accumulation, and alleviating oxidative stress. These initiatives are in preclinical and clinical development and are reviewed herein.</p>
</abstract>
<kwd-group>
<kwd>Friedreich ataxia</kwd>
<kwd>mitochondria</kwd>
<kwd>iron</kwd>
<kwd>experimental therapeutics</kwd>
<kwd>trinucleotide repeat disorders</kwd>
<kwd>sulfur</kwd>
<kwd>mitochondrial</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Friedreich ataxia, an autosomal recessive neuro- and cardiodegenerative disorder with a prevalence of approximately 1 in 50 000 in European populations, is characterized by progressive ataxia of all 4 limbs, dysarthria, areflexia, sensory loss, and muscle fatigability. The neurological signs and symptoms are largely secondary to degeneration of the large sensory neurons of the dorsal root ganglia and spinocerebellar tracts. Skeletal deformities and cardiomyopathy are found in most patients, impaired glucose tolerance and diabetes mellitus are found in ∼30% of patients, and reduced visual acuity and hearing loss are occasionally seen.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812449691">1</xref>
</sup> Onset of symptoms usually occurs around puberty, and most patients are confined to a wheelchair by their late 20s. Myocardial failure and/or arrhythmias are the most common cause of premature death.</p>
<p>Currently, no drugs are approved to treat Friedreich ataxia and the resultant disability, to prolong the life of a patient with Friedreich ataxia, or to cure the disorder. Three biochemical defects guide most current approaches to therapeutic development for Friedreich ataxia: (1) decreased expression of the disease gene, <italic>FXN</italic>, (2) mitochondrial iron accumulation, and (3) oxidative stress. In this review, I present an overview of some of the major therapeutic initiatives based on these 3 biochemical defects, discussing each in turn. For a more comprehensive review of experimental therapeutics for Friedreich ataxia, the reader is referred to the excellent recent reviews by Santos and colleagues,<sup>
<xref ref-type="bibr" rid="bibr2-0883073812449691">2</xref>
</sup> Schmucker and Puccio,<sup>
<xref ref-type="bibr" rid="bibr3-0883073812449691">3</xref>
</sup> and Pandolfo.<sup>
<xref ref-type="bibr" rid="bibr4-0883073812449691">4</xref>
</sup>
</p>
<sec id="section1-0883073812449691">
<title>Decreased Frataxin Expression</title>
<p>Friedreich ataxia is caused by intronic guanine adenine adenine (GAA) repeat expansions in the <italic>FXN</italic> gene, which encodes the protein frataxin. Most patients with Friedreich ataxia (∼96%) have expansions of a GAA repeat in the first intron of both alleles of <italic>FXN</italic>.<sup>
<xref ref-type="bibr" rid="bibr5-0883073812449691">5</xref>
</sup> Normal alleles have 36 or fewer GAA repeats, while disease alleles have from approximately 70 to more than 1700 repeats.<sup>
<xref ref-type="bibr" rid="bibr6-0883073812449691">6</xref>
</sup> The repeat expansions interfere with transcription of the protein frataxin,<sup>
<xref ref-type="bibr" rid="bibr7-0883073812449691">7</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr8-0883073812449691">8</xref>
</sup> and the size of the expansions correlate inversely with age of onset and directly with rate of disease progression.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812449691">1</xref>
</sup> A complete knockout of the murine frataxin gene causes embryonic lethality, indicating that at least some frataxin function is necessary for survival.<sup>
<xref ref-type="bibr" rid="bibr9-0883073812449691">9</xref>
</sup>
</p>
<p>Because the <italic>exonic</italic> sequences of most disease alleles are intact, increasing frataxin expression is an attractive therapeutic target. The mechanism(s) by which GAA repeat expansions decrease expression of <italic>FXN</italic> include(s) hypoacetylation of histones H3 and H4, leading to the possibility that histone deacetylase inhibitors, which can change silent heterochromatin to an active chromatin conformation, might increase frataxin expression. Data supporting this possibility have been reviewed by Gottesfeld,<sup>
<xref ref-type="bibr" rid="bibr10-0883073812449691">10</xref>
</sup> who pioneered the approach. Briefly, histone deacetylase inhibitors have been found that increase frataxin expression in blood lymphocytes of individuals with Friedreich ataxia in vitro,<sup>
<xref ref-type="bibr" rid="bibr11-0883073812449691">11</xref>
</sup> and in vivo in transgenic mice carrying a GAA repeat expansion in the first intron of the murine frataxin gene, without acute toxicity.<sup>
<xref ref-type="bibr" rid="bibr12-0883073812449691">12</xref>
</sup> The RepliGen Corporation (Waltham, Massachusetts) is now advancing lead-candidate histone deacetylase inhibitors through preclinical toxicity studies and into phase 1 clinical trials for Friedreich ataxia.</p>
<p>Recombinant human erythropoietin increases frataxin expression in primary Friedreich ataxia lymphocytes and fibroblasts,<sup>
<xref ref-type="bibr" rid="bibr13-0883073812449691">13</xref>
</sup> without increasing <italic>FXN</italic> mRNA, suggesting a posttranscriptional effect.<sup>
<xref ref-type="bibr" rid="bibr14-0883073812449691">14</xref>
</sup> In open-label, pilot trials of erythropoietin, frataxin expression in blood lymphocytes increased by a mean of 27% (<italic>P</italic> &lt; .01) after 8 weeks of treatment in 7 of 11 individuals with Friedreich ataxia,<sup>
<xref ref-type="bibr" rid="bibr15-0883073812449691">15</xref>
</sup> and Ataxia Rating Scale scores improved after 6 months of treatment.<sup>
<xref ref-type="bibr" rid="bibr16-0883073812449691">16</xref>
</sup> In the latter study, 4 of 8 patients required phlebotomy for elevated hematocrit. Because erythropoietin is an endogenous agonist, cellular regulatory mechanisms might result in desensitization with chronic treatment. In addition, chronic treatment is sometimes associated with a pure red cell aplasia.<sup><xref ref-type="bibr" rid="bibr17-0883073812449691">17</xref><xref ref-type="bibr" rid="bibr18-0883073812449691"/><xref ref-type="bibr" rid="bibr19-0883073812449691"/>–<xref ref-type="bibr" rid="bibr20-0883073812449691">20</xref></sup> In a study of larger single doses of erythropoietin for Friedreich ataxia, a delayed but significant increase in frataxin was noted after 3 months (1 dose) and 6 months (2 doses), and these doses were well tolerated, although Ataxia Rating Scale scores were unchanged from baseline.<sup>
<xref ref-type="bibr" rid="bibr21-0883073812449691">21</xref>
</sup> Erythropoietin mimetics, which might increase frataxin expression without a concomitant increase in hematocrit, are also under investigation.</p>
<p>The PPARg coactivator PGC-1a is downregulated in human Friedreich ataxia cells and Friedreich ataxia mouse models,<sup>
<xref ref-type="bibr" rid="bibr22-0883073812449691">22</xref>
</sup> supporting an approach proposed by Rustin,<sup>
<xref ref-type="bibr" rid="bibr23-0883073812449691">23</xref>
</sup> which is to treat individuals with Friedreich ataxia with the commercially available PPARg agonist pioglitazone, a diabetes drug.<sup>
<xref ref-type="bibr" rid="bibr24-0883073812449691">24</xref>
</sup> A proof-of-concept trial of pioglitazone for the treatment of Friedreich ataxia is in progress in France. Other approaches to increase frataxin include high-throughput drug screens using a frataxin reporter system to identify compounds that increase frataxin expression (in progress); resveratrol, which increases frataxin expression in multiple in vitro Friedreich ataxia models (Joseph P. Sarsero, Fourth International Friedreich’s Ataxia Conference Abstracts, www.curefa.org); and protein replacement therapy. In their approach to protein replacement, Vyas and colleagues found that a fusion of frataxin with the protein transduction domain of the TAT protein (TAT-Frataxin) successfully delivered frataxin to mitochondria in cultured cells from patients and in a severe mouse model of Friedreich ataxia.<sup>
<xref ref-type="bibr" rid="bibr25-0883073812449691">25</xref>
</sup> Injection of TAT-Frataxin into a conditional-knockout mouse model developed by Puccio and colleagues<sup>
<xref ref-type="bibr" rid="bibr26-0883073812449691">26</xref>
</sup> improved growth, increased lifespan by 53%, increased cardiac function, and improved biochemical abnormalities associated with loss of frataxin.<sup>
<xref ref-type="bibr" rid="bibr25-0883073812449691">25</xref>
</sup>
</p>
</sec>
<sec id="section2-0883073812449691">
<title>Mitochondrial Iron Accumulation</title>
<p>Frataxin localizes to the mitochondrial matrix, where it binds iron and is involved in iron-sulfur cluster assembly.<sup>
<xref ref-type="bibr" rid="bibr27-0883073812449691">27</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr28-0883073812449691">28</xref>
</sup> Iron-sulfur clusters are prosthetic groups important for the function of many proteins, both mitochondrial and cytosolic, including aconitase and mitochondrial respiratory complexes I, II, and III. The decrease in frataxin function in Friedreich ataxia results in decreased iron-sulfur cluster assembly; in Friedreich ataxia patients, as well as in yeast and mouse models, this is associated with mitochondrial iron accumulation, cytosolic iron depletion, increased oxidative stress, and mitochondrial dysfunction.<sup><xref ref-type="bibr" rid="bibr26-0883073812449691">26</xref>,<xref ref-type="bibr" rid="bibr29-0883073812449691">29</xref><xref ref-type="bibr" rid="bibr30-0883073812449691"/><xref ref-type="bibr" rid="bibr31-0883073812449691"/><xref ref-type="bibr" rid="bibr32-0883073812449691"/><xref ref-type="bibr" rid="bibr33-0883073812449691"/><xref ref-type="bibr" rid="bibr34-0883073812449691"/><xref ref-type="bibr" rid="bibr35-0883073812449691"/><xref ref-type="bibr" rid="bibr36-0883073812449691"/><xref ref-type="bibr" rid="bibr37-0883073812449691"/><xref ref-type="bibr" rid="bibr38-0883073812449691"/><xref ref-type="bibr" rid="bibr39-0883073812449691"/><xref ref-type="bibr" rid="bibr40-0883073812449691"/><xref ref-type="bibr" rid="bibr41-0883073812449691"/>–<xref ref-type="bibr" rid="bibr42-0883073812449691">42</xref></sup> Because the cellular pathophysiology of Friedreich ataxia includes iron dysregulation and mitochondrial iron accumulation, siderophores are of interest as possible therapeutics for Friedreich ataxia.<sup><xref ref-type="bibr" rid="bibr43-0883073812449691">43</xref><xref ref-type="bibr" rid="bibr44-0883073812449691"/><xref ref-type="bibr" rid="bibr45-0883073812449691"/>–<xref ref-type="bibr" rid="bibr46-0883073812449691">46</xref></sup>
</p>
<p>The most-studied siderophore in the Friedreich ataxia field is deferiprone, a lipid-soluble 1,2-diketo heterocycle that chelates iron. In HEK-293 cells in which <italic>FXN</italic> mRNA was knocked down by RNAi, 50 mM deferiprone increased mitochondrial membrane redox potential, adenosine triphosphate production, and resistance to staurosporine-induced apoptosis.<sup>
<xref ref-type="bibr" rid="bibr42-0883073812449691">42</xref>
</sup> By these measures, deferiprone outperformed the siderophores deferasirox, salicylaldehyde isonicotinoyl hydrazone, and deferoxamine. The affinities of deferiprone, deferasirox, salicylaldehyde isonicotinoyl hydrazone, and deferoxamine for iron (in pM at pH 7.4 for Fe<sup>3+</sup>) are 19.5, 22.5, 27.7, and 26.6, respectively; that is, the order of efficacies in the HEK-293 Friedreich ataxia model (deferiprone &gt; deferasirox = salicylaldehyde isonicotinoyl hydrazone &gt; deferoxamine) correlated inversely with iron affinity, suggesting that a lower affinity for iron might be more efficacious.<sup>
<xref ref-type="bibr" rid="bibr42-0883073812449691">42</xref>
</sup>
</p>
<p>In a small, open trial for 11 Friedreich ataxia patients, deferiprone decreased brain iron by magnetic resonance imaging (MRI).<sup>
<xref ref-type="bibr" rid="bibr46-0883073812449691">46</xref>
</sup> Waldvogel and colleagues had previously observed an increase in iron in the dentate nucleus of the brain in Friedreich ataxia patients using T2-weighted MRI;<sup>
<xref ref-type="bibr" rid="bibr47-0883073812449691">47</xref>
</sup> however, Koeppen and colleagues later demonstrated that total iron in the dentate nucleus of patients with Friedreich ataxia was no different than that of normal controls, and that the signal depression on T2-weighted MRI (because of the paramagnetic effect of iron) was likely the result of a shift of iron into ferritin in non-neuronal cells.<sup>
<xref ref-type="bibr" rid="bibr48-0883073812449691">48</xref>
</sup> In another open-label trial, deferiprone was given to 20 individuals with Friedreich ataxia for 11 months, in combination with the antioxidant idebenone (see below); Ataxia Scale scores remained unchanged, which was interpreted as a stabilization of neurological function (since Ataxia Scale scores usually progress significantly over 11 months), and cardiac wall thicknesses decreased.<sup>
<xref ref-type="bibr" rid="bibr49-0883073812449691">49</xref>
</sup>
</p>
<p>A double-blind, randomized, placebo-controlled phase 2 trial of deferiprone for 80 individuals with Friedreich ataxia was recently completed. In a preliminary report (Arpa and colleagues, Fourth International Friedreich’s Ataxia Conference Abstracts, www.curefa.org), there were no significant overall changes in Ataxia Scale scores, though improvements in posture, gait, and kinetic function were noted in some patients, and treatment was associated with a decrease in left ventricular mass. Low serum ferritin levels were noted in some patients, and there was one case of neutropenia, which resolved on drug withdrawal. (Deferiprone is associated with agranulocytosis in a subset of patients, necessitating weekly blood counts for anyone taking this experimental therapeutic.)</p>
</sec>
<sec id="section3-0883073812449691">
<title>Oxidative Stress</title>
<p>The evidence for oxidative stress in Friedreich ataxia is the subject of an excellent recent review by Armstrong and colleagues.<sup>
<xref ref-type="bibr" rid="bibr50-0883073812449691">50</xref>
</sup> That there should be oxidative stress in Friedreich ataxia, and that it might be difficult to measure directly, is unsurprising. The iron that accumulates in the mitochondria of cells with decreased frataxin function is primarily ferrous. Ferrous iron can generate toxic reactive oxygen species by reducing oxygen to the superoxide radical and reducing hydrogen peroxide to the extremely reactive hydroxyl radical (the Fenton reactions).<sup>
<xref ref-type="bibr" rid="bibr51-0883073812449691">51</xref>
</sup> However, a certain level of physiologic reactive oxygen species is present normally, which can obscure low-level signals from a relatively small number of affected disease cells, and cells with extremes of oxidative stress often die by apoptosis. In the view of this author, the preponderance of evidence, both direct and indirect, supports the hypothesis that oxidative stress contributes to Friedreich ataxia pathophysiology, and thus supports the investigation of antioxidant approaches to treatment.</p>
<p>Idebenone, a short-chain parabenzoquinone derivative with a structure very similar to that of coenzyme Q10, advanced to phase 3 trials for Friedreich ataxia. Like coenzyme Q10, idebenone transfers electrons from complex I and complex II to complex III in the mitochondrial electron transport chain.<sup>
<xref ref-type="bibr" rid="bibr52-0883073812449691">52</xref>
</sup> Open trials and small double-blind placebo-controlled trials indicated some indirect evidence for efficacy of idebenone for the cardiomyopathy of Friedreich ataxia, but little evidence for efficacy for the ataxia of Friedreich ataxia.<sup><xref ref-type="bibr" rid="bibr53-0883073812449691">53</xref><xref ref-type="bibr" rid="bibr54-0883073812449691"/><xref ref-type="bibr" rid="bibr55-0883073812449691"/>–<xref ref-type="bibr" rid="bibr56-0883073812449691">56</xref></sup> In phase 3 trials of idebenone, and in open-label extension studies, there were trends toward improvement in Ataxia Scale scores and cardiac hypertrophy, but statistical significance was not achieved.<sup><xref ref-type="bibr" rid="bibr57-0883073812449691">57</xref><xref ref-type="bibr" rid="bibr58-0883073812449691"/>–<xref ref-type="bibr" rid="bibr59-0883073812449691">59</xref></sup> In all of these studies of idebenone, the drug was safe and well tolerated.</p>
<p>A number of other antioxidants are in preclinical and early clinical development, though little is published as yet regarding evidence for effectiveness in Friedreich ataxia. These antioxidants include EPI-A0001 and EPI-743, both being developed by Edison Pharmaceuticals; Egb-761, a ginkgo biloba extract being developed by Ipsen; OX1, which is being developed by Intellect Neurosciences and may act as both an antioxidant and an iron chelator; mitochondrial radical quenchers, under development by Sid Hecht and colleagues at Arizona State University; and deuterated polyunsaturated fatty acids, which are reinforced against free-radical damage and are under development by Retrotope, Inc. (Los Altos Hills, California).</p>
</sec>
<sec id="section4-0883073812449691">
<title>Conclusion</title>
<p>Cloning of the disease gene for Friedreich ataxia and elucidation of many aspects of the biochemical defects underlying the disorder have led to an explosion of therapeutic initiatives. Ultimately, a combination of therapeutics aimed at each of the 3 categories described above—decreased frataxin expression, mitochondrial iron accumulation, and oxidative stress—may be most effective. The rationale for such a combination approach is that each drug will contribute to efficacy, while balancing side effects (which are inevitable with any drug). Regardless, because therapeutic development is often fraught with unexpected difficulties, the sheer number of initiatives for Friedreich ataxia bodes well for the successful development and approval of effective therapies during the next few years.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>Presented at the Neurobiology of Disease in Children Symposium: Childhood Ataxia, in conjunction with the 40th Annual Meeting of the Child Neurology Society, Savannah, Georgia, October 26, 2011. Supported by grants from the National Institutes of Health. The author wishes to thank Melanie Fridl Ross, MSJ, ELS, for editing this article.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0883073812449691">
<label>Declaration of Conflicting Interests</label>
<p>The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0883073812449691">
<label>Funding</label>
<p>The author disclosed receipt of the following financial support for the research and/or authorship of this article: Supported by grants from the National Institute of Neurological Disorders and Stroke (5R13NS040925-15), the National Institutes of Health Office of Rare Disease Research, the Child Neurology Society, and the National Ataxia Foundation. </p>
</fn>
<fn fn-type="other" id="fn3-0883073812449691">
<label>Ethical Approval</label>
<p>No human or animal studies were performed for this review article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812449691">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cossee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical and genetic abnormalities in patients with Friedreich’s ataxia</article-title>. <source>New Engl J Med</source>. <year>1996</year>;<volume>335</volume>:<fpage>1169</fpage>–<lpage>1175</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812449691">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santos</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lefevre</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sliwa</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities</article-title>. <source>Antioxid Redox Signal</source>. <year>2010</year>;<volume>13</volume>:<fpage>651</fpage>–<lpage>690</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812449691">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmucker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Puccio</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Understanding the molecular mechanisms of Friedreich’s ataxia to develop therapeutic approaches</article-title>. <source>Hum Mol Genet</source>. <year>2010</year>;<volume>19</volume>:<fpage>R103</fpage>–<lpage>R110</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812449691">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>:<fpage>1296</fpage>–<lpage>1303</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812449691">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campuzano</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Montermini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Molto</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>. <article-title>Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion</article-title>. <source>Science</source>. <year>1996</year>;<volume>271</volume>:<fpage>1423</fpage>–<lpage>1427</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812449691">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Molecular pathogenesis of Friedreich’s ataxia</article-title>. <source>Neurol Rev</source>. <year>1999</year>;<volume>56</volume>:<fpage>1201</fpage>–<lpage>1208</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812449691">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohshima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Montermini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Inhibitory effects of expanded GAA-TTC triplet repeats from intron I of the Friedreich Ataxia gene on transcription and replication in vivo</article-title>. <source>J Biol Chem</source>. <year>1998</year>;<volume>273</volume>:<fpage>14588</fpage>–<lpage>14595</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812449691">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakamoto</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich’s ataxia</article-title>. <source>Mol Cell</source>. <year>1999</year>;<volume>3</volume>:<fpage>465</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812449691">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cossee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Puccio</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gansmuller</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation</article-title>. <source>Hum Mol Genetics</source>. <year>2000</year>;<volume>9</volume>:<fpage>1219</fpage>–<lpage>1226</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812449691">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottesfeld</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Small molecules affecting transcription in Friedreich ataxia</article-title>. <source>Pharmacol Ther</source>. <year>2007</year>;<volume>116</volume>:<fpage>236</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812449691">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jenssen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Burnett</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia</article-title>. <source>Nat Chem Biol</source>. <year>2006</year>;<volume>2</volume>:<fpage>551</fpage>–<lpage>558</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812449691">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Soragni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jenssen</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model</article-title>. <source>PLoS One</source>. <year>2008</year>;<volume>3</volume>:<fpage>e1958</fpage>.</citation>
</ref>
<ref id="bibr13-0883073812449691">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sturm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stupphann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kaun</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Recombinant human erythropoietin: effects on frataxin expression in vitro</article-title>. <source>Eur J Clin Invest</source>. <year>2005</year>;<volume>35</volume>:<fpage>711</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812449691">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acquaviva</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Castaldo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression</article-title>. <source>Cerebellum</source>. <year>2008</year>;<volume>7</volume>:<fpage>360</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812449691">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boesch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sturm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Friedreich’s ataxia: clinical pilot trial with recombinant human erythropoietin</article-title>. <source>Ann Neurol</source>. <year>2007</year>;<volume>62</volume>:<fpage>521</fpage>–<lpage>524</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812449691">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boesch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sturm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>:<fpage>1940</fpage>–<lpage>1944</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812449691">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tefferi</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?</article-title> <source>Mayo Clin Proc</source>. <year>2007</year>;<volume>82</volume>:<fpage>1316</fpage>–<lpage>1318</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812449691">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Djulbegovic</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>299</volume>:<fpage>914</fpage>–<lpage>924</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812449691">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sytkowski</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Does erythropoietin have a dark side? Epo signaling and cancer cells</article-title>. <source>Sci STKE</source>. <year>2007;2007</year>:<fpage>pe38</fpage>.</citation>
</ref>
<ref id="bibr20-0883073812449691">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollock</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Horl</surname>
<given-names>WH</given-names>
</name>
<etal/>
</person-group>. <article-title>Pure red cell aplasia induced by erythropoiesis-stimulating agents</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2008</year>;<volume>3</volume>:<fpage>193</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr21-0883073812449691">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacca</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Puorro</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Antenora</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design</article-title>. <source>PLoS ONE</source>. <year>2011</year>;<volume>6</volume>:<fpage>e17627</fpage>.</citation>
</ref>
<ref id="bibr22-0883073812449691">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marmolino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich’s ataxia</article-title>. <source>Hum Mol Genet</source>. <year>2009</year>;<volume>18</volume>:<fpage>2452</fpage>–<lpage>2461</lpage>.</citation>
</ref>
<ref id="bibr23-0883073812449691">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babady</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Carelle</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>Advancements in the pathophysiology of Friedreich’s Ataxia and new prospects for treatments</article-title>. <source>Mol Genet Metab</source>. <year>2007</year>;<volume>92</volume>:<fpage>23</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr24-0883073812449691">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krentz</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2009</year>;<volume>25</volume>:<fpage>112</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr25-0883073812449691">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vyas</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Tomamichel</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Pride</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group>. <article-title>A TAT-Frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich’s ataxia mouse model</article-title>. <source>Hum Mol Genet</source>, <year>2012</year>;<volume>21</volume>:<fpage>1230</fpage>–<lpage>1247</lpage>.</citation>
</ref>
<ref id="bibr26-0883073812449691">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puccio</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cossee</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits</article-title>. <source>Nat Genet</source>. <year>2001</year>;<volume>27</volume>:<fpage>181</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr27-0883073812449691">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muhlenhoff</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Richhardt</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ristow</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins</article-title>. <source>Hum Mol Genet</source>. <year>2002</year>;<volume>11</volume>:<fpage>2025</fpage>–<lpage>2036</lpage>.</citation>
</ref>
<ref id="bibr28-0883073812449691">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muhlenhoff</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Gerber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Richhardt</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lill</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Components involved in assembly and dislocation of iron-sulfur clusters on the scaffold protein Isu1p</article-title>. <source>Embo J</source>. <year>2003</year>;<volume>22</volume>:<fpage>4815</fpage>–<lpage>4825</lpage>.</citation>
</ref>
<ref id="bibr29-0883073812449691">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babcock</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Silva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oaks</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of Frataxin</article-title>. <source>Science</source>. <year>1997</year>;<volume>276</volume>:<fpage>1709</fpage>–<lpage>1712</lpage>.</citation>
</ref>
<ref id="bibr30-0883073812449691">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Roof</surname>
<given-names>DM</given-names>
</name>
</person-group>. <article-title>Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue</article-title>. <source>Nat Genet</source>. <year>1997</year>;<volume>16</volume>:<fpage>352</fpage>–<lpage>357</lpage>.</citation>
</ref>
<ref id="bibr31-0883073812449691">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foury</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cazzalini</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Deletion of the yeast homologue of the human gene associated with Friedreich’s ataxia elicits iron accumulation in mitochondria</article-title>. <source>FEBS Lett</source>. <year>1997</year>;<volume>411</volume>:<fpage>373</fpage>–<lpage>377</lpage>.</citation>
</ref>
<ref id="bibr32-0883073812449691">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radisky</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Babcock</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>JK</given-names>
</name>
</person-group>. <article-title>The yeast frataxin homologue mediates mitochondrial iron efflux: evidence for a mitochondrial iron cycle</article-title>. <source>J Biol Chem</source>. <year>1999</year>;<volume>274</volume>:<fpage>4497</fpage>–<lpage>4499</lpage>.</citation>
</ref>
<ref id="bibr33-0883073812449691">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foury</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain</article-title>. <source>FEBS Letters</source>. <year>1999</year>;<volume>456</volume>:<fpage>281</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr34-0883073812449691">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotig</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Lonlay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chretien</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich’s ataxia</article-title>. <source>Nat Genet</source>. <year>1997</year>;<volume>17</volume>:<fpage>215</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr35-0883073812449691">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradley</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Blake</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Chamberlain</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical, biochemical and molecular genetic correlations in Friedreich’s ataxia</article-title>. <source>Hum Mol Genet</source>. <year>2000</year>;<volume>9</volume>:<fpage>275</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr36-0883073812449691">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia</article-title>. <source>Proc Nat Acad Sci USA</source>. <year>1999</year>;<volume>96</volume>:<fpage>11492</fpage>–<lpage>11495</lpage>.</citation>
</ref>
<ref id="bibr37-0883073812449691">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Rajagopalan</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia</article-title>. <source>Ann Neurol</source>. <year>2001</year>;<volume>49</volume>:<fpage>590</fpage>–<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr38-0883073812449691">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Lech</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Near-infrared muscle spectroscopy in patients with Friedreich’s ataxia</article-title>. <source>Muscle Nerve</source>. <year>2002</year>;<volume>25</volume>:<fpage>664</fpage>–<lpage>673</lpage>.</citation>
</ref>
<ref id="bibr39-0883073812449691">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulz</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Dehmer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schols</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Oxidative stress in patients with Friedreich ataxia</article-title>. <source>Neurology</source>. <year>2000</year>;<volume>55</volume>:<fpage>1719</fpage>–<lpage>1721</lpage>.</citation>
</ref>
<ref id="bibr40-0883073812449691">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emond</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lepage</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vanasse</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Increased levels of plasma malondialdehyde in Friedreich ataxia</article-title>. <source>Neurology</source>. <year>2000</year>;<volume>55</volume>:<fpage>1752</fpage>–<lpage>1753</lpage>.</citation>
</ref>
<ref id="bibr41-0883073812449691">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Besse</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia</article-title>. <source>Hum Mol Genet</source>. <year>2008</year>;<volume>17</volume>:<fpage>2265</fpage>–<lpage>2273</lpage>.</citation>
</ref>
<ref id="bibr42-0883073812449691">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakhlon</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Manning</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Breuer</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation</article-title>. <source>Blood</source>. <year>2008</year>;<volume>112</volume>:<fpage>5219</fpage>–<lpage>5227</lpage>.</citation>
</ref>
<ref id="bibr43-0883073812449691">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richardson</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Mouralian</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ponka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Development of potential iron chelators for the treatment of Friedreich’s ataxia: ligands that mobilize mitochondrial iron</article-title>. <source>Biochim Biophys Acta</source>. <year>2001</year>;<volume>1536</volume>:<fpage>133</fpage>–<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr44-0883073812449691">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richardson</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Friedreich’s ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?</article-title> <source>Expert Opin Investig Drugs</source>. <year>2003</year>;<volume>12</volume>:<fpage>235</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr45-0883073812449691">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voncken</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ioannou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Delatycki</surname>
<given-names>MB</given-names>
</name>
</person-group>. <article-title>Friedreich ataxia-update on pathogenesis and possible therapies</article-title>. <source>Neurogenetics</source>. <year>2004</year>;<volume>5</volume>:<fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr46-0883073812449691">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boddaert</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Le Quan Sang</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Rotig</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Selective iron chelation in Friedreich ataxia. Biological and clinical implications</article-title>. <source>Blood</source>. <year>2007</year>;<volume>110</volume>:<fpage>401</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr47-0883073812449691">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waldvogel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Gelderen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hallett</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Increased iron in the dentate nucleus of patients with Friedreich’s ataxia</article-title>. <source>Ann Neurol</source>. <year>1999</year>;<volume>46</volume>:<fpage>123</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr48-0883073812449691">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koeppen</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Michael</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Knutson</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>. <article-title>The dentate nucleus in Friedreich’s ataxia: the role of iron-responsive proteins</article-title>. <source>Acta Neuropathol (Berl)</source>. <year>2007</year>;<volume>114</volume>:<fpage>163</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr49-0883073812449691">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velasco-Sanchez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Aracil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Montero</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia</article-title>. <source>Cerebellum</source>. <year>2011</year>;<volume>10</volume>:<fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr50-0883073812449691">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Khdour</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hecht</surname>
<given-names>SM</given-names>
</name>
</person-group>. <article-title>Does oxidative stress contribute to the pathology of Friedreich’s ataxia? A radical question</article-title>. <source>Faseb J</source>. <year>2010</year>;<volume>24</volume>:<fpage>2152</fpage>–<lpage>2163</lpage>.</citation>
</ref>
<ref id="bibr51-0883073812449691">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horton</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Fairhurst</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Lipid peroxidation and mechanisms of toxicity</article-title>. <source>CRC Crit Rev Toxicol</source>. <year>1987</year>;<volume>18</volume>:<fpage>27</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr52-0883073812449691">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugiyama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs</article-title>. <source>J Pharmacobiodyn</source>. <year>1985</year>;<volume>8</volume>:<fpage>1006</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr53-0883073812449691">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hausse</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Aggoun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia</article-title>. <source>Heart</source>. <year>2002</year>;<volume>87</volume>:<fpage>346</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr54-0883073812449691">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Solari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Torta</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marano</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>60</volume>:<fpage>1676</fpage>–<lpage>1679</lpage>.</citation>
</ref>
<ref id="bibr55-0883073812449691">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buyse</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Di Salvo</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>60</volume>:<fpage>1679</fpage>–<lpage>1681</lpage>.</citation>
</ref>
<ref id="bibr56-0883073812449691">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Prospero</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Sumner</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Penzak</surname>
<given-names>SR</given-names>
</name>
<etal/>
</person-group>. <article-title>Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>2007</year>;<volume>64</volume>:<fpage>803</fpage>–<lpage>808</lpage>.</citation>
</ref>
<ref id="bibr57-0883073812449691">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>2010</year>;<volume>67</volume>:<fpage>941</fpage>–<lpage>947</lpage>.</citation>
</ref>
<ref id="bibr58-0883073812449691">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meier</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Rummey</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study</article-title>. <source>J Neurol</source>. <year>2012</year>;<volume>259</volume>:<fpage>284</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr59-0883073812449691">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lagedrost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>MS</given-names>
</name>
<etal/>
</person-group>. <article-title>Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)</article-title>. <source>Am Heart J</source>. <year>2011</year>;<volume>161</volume>:<fpage>639</fpage>–<lpage>645</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>